SCHEMBL3928779

SCHEMBL3928779

CC(C)N1CCCN(C(=O)c2ccc(C(O)c3ccccc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.62
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HRH3 Q9Y5N1 8/20 0.58
CHRM1 P11229 1/20 0.56
MAOB P27338 1/20 0.55
SLC6A4 P31645 1/20 0.53
POLB P06746 1/20 0.49
OPRD1 P41143 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926523 0.95 MAOB (0.60) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL1447408 0.88 HRH3 (0.71) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL3915425 0.87 CHRNA7 (0.68) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL3926220 0.84 CHRNA7 (0.65) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL5119237 0.82 CHRNA7 (0.62) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL12777929 0.82 MAOB (0.68) CHRNA7KMT2AALDH1A1HRH3MAOB
Hydrochloric Acid SCHEMBL27615790 0.82 MAOB (0.57) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL3919877 0.81 CHRNA7 (0.62) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL15624886 0.80 CHRNA7 (0.94) CHRNA7MEN1KMT2AALDH1A1LMNA
SCHEMBL6633015 0.80 CHRNA7 (0.70) CHRNA7MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038269-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-25 EP claimed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US claimed
WO-2008002816-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO claimed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
WO-2008002816-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 CHRNA7 410/4885MEN1 2916/4885KMT2A 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.